Table 1.
Baseline characteristics of the study population, showing group size, age and the absolute and relative frequencies of depression, use of other medications (insulin, oral antidiabetics, antidepressants) and comorbid conditions for males and females in the statin-treated and in the matched control group.
| Statin-treated patients | Non-statin-treated patients | |||
|---|---|---|---|---|
| Male | Female | Male | Female | |
| N | 166,979 | 170,259 | 500,937 | 510,777 |
| Age (mean +/– SD) | 64.91 +/- 10.86 | 68.88 +/– 10.41 | 64.91 +/– 10.86 | 68.88 +/– 10.41 |
| Depression (F32–F33) | 2,947* (1.76%) | 6,774* (3.98%) | 6,907 (1.38%) | 15,953 (3.12%) |
| Antidepressants | 35,379* (21.19%) | 63,534* (37.32%) | 73,675 (14.71%) | 140,846 (27.57%) |
| Insulin | 10,697* (6.41%) | 11,348* (6.67%) | 6,281 (1.25%) | 6,296 (1.23%) |
| Oral antidiabetics | 32,639* (19.55%) | 30,950* (18.18%) | 26,605 (5.31%) | 25,462 (4.98%) |
| CVD (I20-I25) | 32,611* (19.53%) | 20,803* (12.22%) | 21,733 (4.34%) | 19,631 (3.84%) |
| Stroke (I63, I64) | 4,367* (2.62%) | 3,684* (2.16%) | 5,826 (1.16%) | 5,860 (1.15%) |
| Diseases of arteries (I70–I79) | 10,552* (6.32%) | 7,569* (4.45%) | 13,227 (2.64%) | 10,415 (2.04%) |
| Overweight and obesity (E66) | 7,164* (4.29%) | 7,149* (4.20%) | 8,384 (1.67%) | 11,061 (2.17%) |
| Hypothyroidism (E02, E03) | 1,239* (0.74%) | 3,277* (1.92%) | 2,551 (0.51%) | 6,735 (1.32%) |
| Alzheimer's disease (F00, G30) | 547* (0.33%) | 990* (0.58%) | 2,537 (0.51%) | 4,381 (0.86%) |
| Pain (R52) | 195* (0.12%) | 302 (0.18%) | 732 (0.15%) | 1,003 (0.20%) |
| Sleep disorders (G47) | 2,806* (1.68%) | 951* (0.56%) | 4,624 (0.92%) | 1,878 (0.37%) |
SD, standard deviation; CVD, cardiovascular disease, Asterisks denote statistically significant differences between statin- and non-statin treated patients;
**p < 0.01,
*
p < 0.05.